Hospital Course and Outcomes of Patients Hospitalized for COVID-19, by Age Group, 6 Hospitals, United States, July to August 2021, N = 759
| . | <1 Years (n = 176) . | 1–4 Years (n = 122) . | 5–11 Years (n = 143) . | 12–17 Years (n = 272) . | 18–20 Years (n = 46) . |
|---|---|---|---|---|---|
| Hospital duration, days, median (IQR) | 2 (1–4) | 3 (2–5) | 2 (1–5) | 4 (2–7) | 6 (2–11) |
| IMV duration, days, median (IQR) | 6 (4.5–12.5) | 6 (1–16) | 5.5 (1–11) | 9.5 (5–23) | 17 (7–29) |
| ICU requirement | |||||
| Any admission, n (%) | 34 (19.3) | 31 (25.4) | 37 (25.9) | 108 (39.7) | 17 (37.0) |
| Duration, d, median (IQR) | 3 (1–7) | 3 (2–5) | 3 (1–7) | 4 (2–8) | 6 (4–11) |
| Treatments, n (%) | |||||
| Remdesivir | 22 (12.5) | 30 (24.6) | 36 (25.2) | 139 (51.1) | 29 (63.0) |
| Baricitinib | 0 (0) | 0 (0) | 1 (0.7) | 8 (2.9) | 1 (2.2) |
| Tocilizumab | 2 (1.1) | 1 (0.8) | 4 (2.8) | 21 (7.7) | 4 (8.7) |
| Other monoclonal antibody | 0 (0) | 0 (0) | 1 (0.7) | 11 (4.0) | 5 (10.9) |
| Glucocorticoid | 41 (23.3) | 64 (52.5) | 70 (49.0) | 186 (68.4) | 33 (71.7) |
| Dexamethasone | 36 (20.5) | 54 (44.3) | 50 (35.0) | 142 (52.2) | 30 (65.2) |
| Antibiotic | 97 (55.1) | 69 (56.6) | 91 (63.6) | 154 (56.6) | 32 (69.6) |
| Anticoagulation | 9 (5.1) | 11 (9.0) | 27 (18.9) | 161 (59.2) | 30 (65.2) |
| Vasoactive support | 6 (3.4) | 2 (1.6) | 5 (3.5) | 21 (7.7) | 5 (10.9) |
| Highest respiratory support, n (%) | |||||
| Nasal cannula | 22 (12.5) | 14 (11.5) | 24 (16.8) | 51 (18.8) | 15 (32.6) |
| HFNC | 43 (24.4) | 32 (26.2) | 14 (9.8) | 53 (19.5) | 7 (15.2) |
| BiPAP or CPAP | 5 (2.8) | 10 (8.2) | 11 (7.7) | 43 (15.8) | 7 (15.2) |
| IMV | 12 (6.8) | 7 (5.7) | 11 (7.7) | 26 (9.6) | 6 (13.0) |
| ECMOa | 1 (0.6) | 1 (0.8) | 1 (0.7) | 5 (1.8) | 2 (4.3) |
| Complicationsbn (%) | |||||
| Viral pneumonia | 31 (17.6) | 42 (34.4) | 48 (33.6) | 149 (54.8) | 28 (60.9) |
| Bacterial pneumonia | 11 (6.3) | 10 (8.2) | 15 (10.5) | 24 (8.8) | 7 (15.2) |
| Bronchiolitis | 38 (21.6) | 18 (14.8) | 0 (0) | 0 (0) | 0 (0) |
| Pleural effusion | 2 (1.1) | 4 (3.3) | 5 (3.5) | 26 (9.6) | 4 (8.7) |
| Discharge diagnosis,b n (%) | |||||
| COVID-19 | 159 (90.3) | 108 (88.5) | 121 (84.6) | 244 (89.7) | 42 (91.3) |
| Pneumonia | 16 (9.1) | 36 (29.5) | 44 (30.8) | 112 (41.2) | 13 (28.3) |
| COVID-19 pneumonia | 13 (7.4) | 35 (28.7) | 38 (26.6) | 108 (39.7) | 13 (28.3) |
| Acute respiratory failure | 33 (18.8) | 29 (23.8) | 23 (16.1) | 71 (26.1) | 15 (32.6) |
| Bronchiolitis | 40 (22.7) | 18 (14.8) | 0 (0) | 0 (0) | 0 (0) |
| RSV | 39 (22.2) | 20 (16.4) | 1 (0.7) | 2 (0.7) | 0 (0) |
| Outcome, n (%) | |||||
| Discharged on oxygenc | 4 (2.3) | 8 (6.6) | 7 (4.9) | 12 (4.4) | 2 (4.3) |
| New mobility restriction | 0 (0) | 0 (0) | 3 (2.1) | 6 (2.2) | 2 (4.3) |
| Died | 2 (1.1) | 0 (0) | 1 (0.7) | 8 (2.9) | 0 (0) |
| . | <1 Years (n = 176) . | 1–4 Years (n = 122) . | 5–11 Years (n = 143) . | 12–17 Years (n = 272) . | 18–20 Years (n = 46) . |
|---|---|---|---|---|---|
| Hospital duration, days, median (IQR) | 2 (1–4) | 3 (2–5) | 2 (1–5) | 4 (2–7) | 6 (2–11) |
| IMV duration, days, median (IQR) | 6 (4.5–12.5) | 6 (1–16) | 5.5 (1–11) | 9.5 (5–23) | 17 (7–29) |
| ICU requirement | |||||
| Any admission, n (%) | 34 (19.3) | 31 (25.4) | 37 (25.9) | 108 (39.7) | 17 (37.0) |
| Duration, d, median (IQR) | 3 (1–7) | 3 (2–5) | 3 (1–7) | 4 (2–8) | 6 (4–11) |
| Treatments, n (%) | |||||
| Remdesivir | 22 (12.5) | 30 (24.6) | 36 (25.2) | 139 (51.1) | 29 (63.0) |
| Baricitinib | 0 (0) | 0 (0) | 1 (0.7) | 8 (2.9) | 1 (2.2) |
| Tocilizumab | 2 (1.1) | 1 (0.8) | 4 (2.8) | 21 (7.7) | 4 (8.7) |
| Other monoclonal antibody | 0 (0) | 0 (0) | 1 (0.7) | 11 (4.0) | 5 (10.9) |
| Glucocorticoid | 41 (23.3) | 64 (52.5) | 70 (49.0) | 186 (68.4) | 33 (71.7) |
| Dexamethasone | 36 (20.5) | 54 (44.3) | 50 (35.0) | 142 (52.2) | 30 (65.2) |
| Antibiotic | 97 (55.1) | 69 (56.6) | 91 (63.6) | 154 (56.6) | 32 (69.6) |
| Anticoagulation | 9 (5.1) | 11 (9.0) | 27 (18.9) | 161 (59.2) | 30 (65.2) |
| Vasoactive support | 6 (3.4) | 2 (1.6) | 5 (3.5) | 21 (7.7) | 5 (10.9) |
| Highest respiratory support, n (%) | |||||
| Nasal cannula | 22 (12.5) | 14 (11.5) | 24 (16.8) | 51 (18.8) | 15 (32.6) |
| HFNC | 43 (24.4) | 32 (26.2) | 14 (9.8) | 53 (19.5) | 7 (15.2) |
| BiPAP or CPAP | 5 (2.8) | 10 (8.2) | 11 (7.7) | 43 (15.8) | 7 (15.2) |
| IMV | 12 (6.8) | 7 (5.7) | 11 (7.7) | 26 (9.6) | 6 (13.0) |
| ECMOa | 1 (0.6) | 1 (0.8) | 1 (0.7) | 5 (1.8) | 2 (4.3) |
| Complicationsbn (%) | |||||
| Viral pneumonia | 31 (17.6) | 42 (34.4) | 48 (33.6) | 149 (54.8) | 28 (60.9) |
| Bacterial pneumonia | 11 (6.3) | 10 (8.2) | 15 (10.5) | 24 (8.8) | 7 (15.2) |
| Bronchiolitis | 38 (21.6) | 18 (14.8) | 0 (0) | 0 (0) | 0 (0) |
| Pleural effusion | 2 (1.1) | 4 (3.3) | 5 (3.5) | 26 (9.6) | 4 (8.7) |
| Discharge diagnosis,b n (%) | |||||
| COVID-19 | 159 (90.3) | 108 (88.5) | 121 (84.6) | 244 (89.7) | 42 (91.3) |
| Pneumonia | 16 (9.1) | 36 (29.5) | 44 (30.8) | 112 (41.2) | 13 (28.3) |
| COVID-19 pneumonia | 13 (7.4) | 35 (28.7) | 38 (26.6) | 108 (39.7) | 13 (28.3) |
| Acute respiratory failure | 33 (18.8) | 29 (23.8) | 23 (16.1) | 71 (26.1) | 15 (32.6) |
| Bronchiolitis | 40 (22.7) | 18 (14.8) | 0 (0) | 0 (0) | 0 (0) |
| RSV | 39 (22.2) | 20 (16.4) | 1 (0.7) | 2 (0.7) | 0 (0) |
| Outcome, n (%) | |||||
| Discharged on oxygenc | 4 (2.3) | 8 (6.6) | 7 (4.9) | 12 (4.4) | 2 (4.3) |
| New mobility restriction | 0 (0) | 0 (0) | 3 (2.1) | 6 (2.2) | 2 (4.3) |
| Died | 2 (1.1) | 0 (0) | 1 (0.7) | 8 (2.9) | 0 (0) |
ECMO, extracorporeal membrane oxygenation.
a Patients receiving IMV include those receiving ECMO.
b List is not exhaustive but includes the top 3 responses in each age category.
c Includes 9 patients noted to have chronic respiratory failure before hospitalization.